Saturday, 31 October 2026European Markets

70% Drop In TERACT BS Stock: Should It Be Time To Sell?

Loading stream...
(vianews) - teract bs (terbs.pa), listed on the cac 40 index, experienced an astonishing 70% fall from eur0.10 to eur0.03 by 16:19 est on monday; this drop occurred despite overall cac 40 index rising 1.32% to eur7,324.80 following an upward trend. teract bs's last closing price was eur0.10, which is below its 52-week high of eur0.10. investors have noted this dip and are closely watching for signs that teract's financial health and business prospects might have worsened.

yearly analysis

based on its current stock price of eur0.03, teract bs has reached its 52-week low point over the last year, meaning that investors should carefully consider all relevant factors before making investment decisions in teract bs. it would also be wise to assess factors such as its financial health, industry trends, and overall market conditions prior to investing.

technical analysis

moving average analysis: teract bsteract bs's current stock price of eur0.06 falls significantly below both its 50-day and 200-day moving averages, both set at eur0.10 respectively, suggesting an imminent downward trend in its share price over short and long terms. investors may be alarmed at this trend as moving averages provide technical indicators of the stock's price trend and widening gaps between its current price and moving averages could suggest further downward movement of its share price. it should be remembered, however, that moving averages are only one indicator used to analyze a stock's performance; other considerations like fundamental analysis as well as market conditions must also be taken into account when analyzing performance of any particular stock. more news about teract bs (terbs.pa).
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com